A number of companies issued important announcements, and Mingde Biotech repurchased about 3500 million shares.
LONGi Green Energy: Moderately raised the planned scale of module production in March 2024.
LONGi Green Energy said in its latest investor event survey that from a global perspective, the current module** is less than 1 yuan, and the cost advantage of photovoltaic power generation is very prominent, which will further promote the full release of global potential demand. Affected by the Spring Festival holiday and cold weather, coupled with the short-term destocking pressure in some markets, the PV market demand in the first quarter of 2024 is relatively light. With the elimination of seasonal factors and the easing of industry inventory pressure, global PV demand will gradually begin to recover, especially when the current module is at the bottom, which will trigger the initiative of downstream market demand**. The global volume is expected to grow by 20% annually in 2024, and the industry's module production schedule has started to improve since March 2024, depending on the level of final demand release. Combined with the changes in PV market demand and the company's orders, the company moderately increased the module production schedule in March 2024 to ensure the product demand of domestic and foreign customers.
Huadong Medicine: The subsidiary received the notice of acceptance of registration of linaercept injection for injection
The wholly-owned subsidiary, Sino-US Huadong Pharmaceutical***, received the "Notice of Acceptance" (acceptance number: JXSS2400016) issued by the National Medical Products Administration (NMPA), which stated that the marketing authorization application for Lilong Saipu for injection (Aralyst)* pericarditis (RP) submitted by the Sino-US East China Registrant** has been accepted. Rilonacept for injection for pericarditis (RP) has been accepted.
Haid Group: Net profit of 27 in fiscal year 20239.4 billion yuan, down 543］
Haid Group announced its 2023 annual performance report, and it is expected that the company will achieve operating income of 1161 in 20234.1 billion yuan, a year-on-year increase of 1091%；It is expected that the company will achieve a net profit attributable to shareholders of listed companies for the whole year of 279.4 billion yuan, down 543%。
Matilda Biotech: 17.5 billion to 3$500 million repurchase**].
Matilda Biotech announced that it intends to repurchase shares, repurchasing ** in 17.5 billion to 3Between 500 million yuan, the ** of the repurchased shares shall not exceed 23 yuan shares.